The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
16/11/2023
Faizy Ahmadzay Z, Georgiadis S, Pons M, Hetland M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Loft A, Castrejon I, Otero-Valera L, Zavada J, Pavelka K, Relas H, Kuusalo L, Moeller B, Nissen M, Rotar Z, Perdan Pirkmajer K, Santos Oliveira D, Cruz-Machado A, Michelsen B, Kristianslund E, Gudbjornsson B, Grondal G, Laas K, Hellamand P, Sari I, Di Giuseppe D, Østergaard M, Ørnbjerg L
ACR 2023
Faizy Ahmadzay Z, Georgiadis S, Pons M, Hetland M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Loft A, Castrejon I, Otero-Valera L, Zavada J, Pavelka K, Relas H, Kuusalo L, Moeller B, Nissen M, Rotar Z, Perdan Pirkmajer K, Santos Oliveira D, Cruz-Machado A, Michelsen B, Kristianslund E, Gudbjornsson B, Grondal G, Laas K, Hellamand P, Sari I, Di Giuseppe D, Østergaard M, Ørnbjerg L. The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-smoking-status-on-one-year-secukinumab-retention-rate-in-1684-patients-with-psa-real-world-results-from-the-eurospa-collaboration/.
https://acrabstracts.org/abstract/the-impact-of-smoking-status-on-one-year-secukinumab-retention-rate-in-1684-patients-with-psa-real-world-results-from-the-eurospa-collaboration/